Krebs Biochemicals & Industries Intrinsic Value
Krebs Biochemicals & Industries (KREBSBIO) median intrinsic value is ₹24.55 from 1 valuation models (range ₹25–₹25), vs current price ₹57.31 — -57.2% downside (Trading Above Calculated Value), margin of safety -100.0%. See KREBSBIO price to book ratio to compare market price against book value per share.
KREBSBIO Valuation Methods Summary — DCF, Graham Number & P/E
Krebs Biochemicals & Industries intrinsic value across 1 models vs current price ₹57.31 — upside/downside and value range per method. Check KREBSBIO market value to track the company's total market size over time.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Revenue Multiple Method | revenue | ₹24.55 | ₹22.10 - ₹27.01 | -57.2% | Revenue/Share: ₹12.27, P/S: 2.0x |
KREBSBIO Intrinsic Value vs Market Price — All Valuation Models
Krebs Biochemicals & Industries fair value range ₹25–₹25 vs current market price ₹57.31 across 1 valuation models. For current market price and key ratios, visit KREBSBIO share price screener.
KREBSBIO Intrinsic Value Analysis — Undervalued or Overvalued?
Krebs Biochemicals & Industries median intrinsic value ₹24.55, current price ₹57.31 — Trading Above Calculated Value by 57.2%, margin of safety -100.0%.
What is the intrinsic value of KREBSBIO?
Based on our comprehensive analysis using 1 different valuation methods, the estimated intrinsic value of Krebs Biochemicals & Industries (KREBSBIO) is ₹24.55 (median value). With the current market price of ₹57.31, this represents a -57.2% variance from our estimated fair value.
The valuation range spans from ₹24.55 to ₹24.55, indicating ₹24.55 - ₹24.55.
Is KREBSBIO undervalued or overvalued?
Based on our multi-method analysis, Krebs Biochemicals & Industries (KREBSBIO) appears to be trading above calculated value by approximately 57.2%.
KREBSBIO Financial Health — Key Ratios vs Industry Benchmarks
Krebs Biochemicals & Industries financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 0.05 | Industry Standard: 2.0+ | Below 1.5 | Measures short-term liquidity capacity |
| Return on Equity | 8.6% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | -16.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.17x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
KREBSBIO Cash Flow Quality — Operating & Free Cash Flow
Krebs Biochemicals & Industries operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-8 Cr | ₹-11 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹2 Cr | ₹-2 Cr | Positive Operating Cash Flow | 6/10 |
| March 2023 | ₹-25 Cr | ₹-32 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹-17 Cr | ₹-29 Cr | Negative Cash Flow | 3/10 |
| March 2021 | ₹-15 Cr | ₹-27 Cr | Negative Cash Flow | 3/10 |